141 related articles for article (PubMed ID: 19641175)
21. [Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay].
Harlé A; Dubois C; Rouyer M; Merlin JL
Ann Biol Clin (Paris); 2013; 71(5):603-7. PubMed ID: 24113449
[TBL] [Abstract][Full Text] [Related]
22. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma.
Angulo B; García-García E; Martínez R; Suárez-Gauthier A; Conde E; Hidalgo M; López-Ríos F
J Mol Diagn; 2010 May; 12(3):292-9. PubMed ID: 20203003
[TBL] [Abstract][Full Text] [Related]
23. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
24. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
25. Sensitive quantification of somatic mutations using molecular inversion probes.
Hirani R; Connolly AR; Putral L; Dobrovic A; Trau M
Anal Chem; 2011 Nov; 83(21):8215-21. PubMed ID: 21942816
[TBL] [Abstract][Full Text] [Related]
26. Correlation between the presence of KRAS mutation and the morphometric characteristics of colorectal carcinoma cell nuclei.
Greenberg A; Hershkovitz D; Sabo E
Anal Quant Cytopathol Histpathol; 2014 Feb; 36(1):23-31. PubMed ID: 24902368
[TBL] [Abstract][Full Text] [Related]
27. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis.
Lecomte T; Berger A; Zinzindohoué F; Micard S; Landi B; Blons H; Beaune P; Cugnenc PH; Laurent-Puig P
Int J Cancer; 2002 Aug; 100(5):542-8. PubMed ID: 12124803
[TBL] [Abstract][Full Text] [Related]
28. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
[No Abstract] [Full Text] [Related]
29. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
30. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
31. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.
Seruca R; Velho S; Oliveira C; Leite M; Matos P; Jordan P
Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):5-9. PubMed ID: 19210107
[No Abstract] [Full Text] [Related]
32. KRAS mutation analysis in a complex molecular diagnostic referral practice: the need for test redundancy.
Pang B; Ong CW; Chong ML; Muliana-Ismail T; Soong R; Salto-Tellez M
Pathology; 2012 Dec; 44(7):655-7. PubMed ID: 23172084
[No Abstract] [Full Text] [Related]
33. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
[TBL] [Abstract][Full Text] [Related]
34. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D; Loupakis F; Vincenzi B; Floriani I; Stasi I; Canestrari E; Rulli E; Maltese PE; Andreoni F; Masi G; Graziano F; Baldi GG; Salvatore L; Russo A; Perrone G; Tommasino MR; Magnani M; Falcone A; Tonini G; Ruzzo A
Oncologist; 2008 Dec; 13(12):1270-5. PubMed ID: 19056857
[TBL] [Abstract][Full Text] [Related]
35. Circulating free DNA in a screening program for early colorectal cancer detection.
Perrone F; Lampis A; Bertan C; Verderio P; Ciniselli CM; Pizzamiglio S; Frattini M; Nucifora M; Molinari F; Gallino G; Gariboldi M; Meroni E; Leo E; Pierotti MA; Pilotti S
Tumori; 2014; 100(2):115-21. PubMed ID: 24852853
[TBL] [Abstract][Full Text] [Related]
36. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
37. Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.
Zhao Y; Miyashita K; Ando T; Kakeji Y; Yamanaka T; Taguchi K; Ushijima T; Oda S; Maehara Y
Gene; 2008 Nov; 423(2):188-93. PubMed ID: 18692554
[TBL] [Abstract][Full Text] [Related]
38. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
39. KRAS and TP53 mutations in colorectal carcinoma.
Al-Kuraya KS
Saudi J Gastroenterol; 2009; 15(4):217-9. PubMed ID: 19794264
[No Abstract] [Full Text] [Related]
40. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.
Kobunai T; Watanabe T; Yamamoto Y; Eshima K
Biochem Biophys Res Commun; 2010 Apr; 395(1):158-62. PubMed ID: 20361930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
